Navigation Links
ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits
Date:5/3/2012

CHARLOTTESVILLE, Va., May 3, 2012 /PRNewswire/ -- ZyGEM Corp. Ltd., a developer and marketer of innovative products for the analysis of DNA and other nucleic acids, today announced it has entered into a non-exclusive agreement with TATAA Biocenter for distribution of ZyGEM's DNA and RNA extraction products in Sweden and other selected countries worldwide.  TATAA Biocenter is a leading provider of quantitative real-time PCR (qPCR) services and products.  This new agreement is the latest in a series of distribution agreements for ZyGEM's DNA and RNA extraction kits with life science distributors globally.

ZyGEM's line of nucleic acid extraction kits feature optimized formulations of proprietary enzymatic technologies that use a single-tube process to provide complete extraction of high quality DNA or RNA from specific sample types rapidly and cost effectively.  Its prepGEM™, forensicGEM™, livestockGEM™ and RNAGEM™ family of products enables nucleic acid extraction from diverse sample types for human and animal DNA and RNA testing.

"We are very pleased to be partnering with qPCR pioneer TATAA Biocenter to expand the availability of our DNA and RNA extraction products," said Paul Kinnon, CEO of ZyGEM.  "TATAA is synonymous with excellence in qPCR, and this agreement is another example of our strategy of working with diverse partners to bring the advantages of our nucleic acid extraction technologies to researchers worldwide."

Founded in 2001 by pioneers in quantitative PCR, TATAA Biocenter is Europe's leading provider of gene expression profiling services and a prime organizer of training in qPCR and other molecular techniques to quant
'/>"/>

SOURCE ZyGEM Corp. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ZyGEM and Advalytix Partner to Produce Innovative DNA Extraction Products
2. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
3. ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe
4. ZyGEM Releases Application Note Showing its DNA Extraction Kits Rapidly Produce High Yields of Quality DNA
5. ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicons Research and Diagnostic Products
6. ZyGEM Releases Data Confirming its prepGEM(R) Insect Kit is a Simple, Rapid Method for Extracting Insect DNA for Species Identification
7. ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan
8. Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva
9. ZyGEM Strengthens Senior Management Team With New Appointments
10. Application Note Shows ZyGEMs forensicGEM® Tissue Facilitates Forensic Casework by Rapidly and Reproducibly Extracting DNA From Human Hair
11. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
(Date:7/28/2015)... NESS ZIONA, Israel ... CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company ... repair products, today announced that Shomrat Shurtz has ... September 20, 2015.      (Photo: ... brings over 25 years of experience in marketing, ...
(Date:7/28/2015)... , July 28, 2015  Faced with increasing ... are palliative rather than symptomatic, the global healthcare ... existing therapies capable of curing or significantly changing ... starting to look towards regenerative medicine as a ... new paradigm in human health with the potential ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... LLC announced today that the first patient has ... support a new fixed-dose combination (FDC) therapy for ... known as 572-Trii, will combine the investigational integrase ... reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... could jumpstart the promising field of cell therapy, in which ... of diseases and tissue defects, researchers at Brigham and Women,s ... the key challenges associated with the procedure: control of the ... reported in the journal Biomaterials on January 26, ...
... has become a standard tool in the search for ... disaster, but until now there has been very little ... policy challenges associated with this new use of genetic ... National Institutes of Health (NIH) has awarded Carnegie ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... measure organic contaminants in human body fluids, the National ... four new Standard Reference Materials (SRMs) available for purchase. ... and Prevention (CDC), the human milk and serum SRMs ... pesticides, commonly found in the U.S. population. Scientists at ...
... Netherlands: For the first time, researchers have been able ... of IVF treatment in blood. Dr. Cathy Allen, from the ... the European Society of Human Reproduction and Embryology today (Wednesday ... works for some patients but not for others. Previous ...
Cached Biology News:Genetically engineered mice yield clues to 'knocking out' cancer 2NIST issues human milk and blood serum SRMs for contaminant measurements 2Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3